Doug BA - Dyadic International Executive Development
| DYAI Stock | USD 1.71 0.16 8.56% |
Executive
Doug BA is Executive Development of Dyadic International
| Address | 1044 North U.S. Highway One, Jupiter, FL, United States, 33477-5094 |
| Phone | 561 743 8333 |
| Web | https://www.dyadic.com |
Dyadic International Management Efficiency
The company has return on total asset (ROA) of (0.4628) % which means that it has lost $0.4628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2738) %, meaning that it created substantial loss on money invested by shareholders. Dyadic International's management efficiency ratios could be used to measure how well Dyadic International manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.87. The Dyadic International's current Return On Capital Employed is estimated to increase to -1.31. The current Total Assets is estimated to decrease to about 7.8 M. The current Other Assets is estimated to decrease to 6,604Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Arthur Hanson | Champions Oncology | N/A | |
| Paige Mahaney | C4 Therapeutics | N/A | |
| Marc MD | Pmv Pharmaceuticals | N/A | |
| Joshua JD | AN2 Therapeutics | 46 | |
| Anne DVM | Molecular Partners AG | N/A | |
| Jennifer Huber | AN2 Therapeutics | N/A | |
| Leonard MD | C4 Therapeutics | 62 | |
| Marc MD | Edgewise Therapeutics | 67 | |
| Nicole Esq | HCW Biologics | N/A | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Ambarish Shah | DiaMedica Therapeutics | N/A | |
| William Winston | Werewolf Therapeutics | N/A | |
| Kendra Adams | C4 Therapeutics | N/A | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Roy Pollock | C4 Therapeutics | N/A | |
| John JD | Edgewise Therapeutics | 60 | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| Jolie JD | C4 Therapeutics | 47 | |
| Lee Flowers | HCW Biologics | 78 | |
| Michael Carulli | Pmv Pharmaceuticals | 50 | |
Management Performance
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.46 |
Dyadic International Leadership Team
Elected by the shareholders, the Dyadic International's board of directors comprises two types of representatives: Dyadic International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dyadic. The board's role is to monitor Dyadic International's management team and ensure that shareholders' interests are well served. Dyadic International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dyadic International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Emalfarb, Founder, CEO and President Director and Chairman of Nominating Committee | ||
| Joseph Hazelton, Chief Officer | ||
| Doug BA, Executive Development | ||
| Ronen Tchelet, VP of Bus. Devel. for Europe | ||
| Ana Rodriguez, Secretary Board |
Dyadic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dyadic International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (5.29) % | ||||
| Current Valuation | 46.05 M | ||||
| Shares Outstanding | 29.48 M | ||||
| Shares Owned By Insiders | 30.21 % | ||||
| Shares Owned By Institutions | 16.01 % | ||||
| Number Of Shares Shorted | 164.78 K | ||||
| Price To Earning | (18.70) X | ||||
| Price To Book | 14.83 X |
Currently Active Assets on Macroaxis
When determining whether Dyadic International offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dyadic International's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dyadic International Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dyadic International Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyadic International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Dyadic Stock please use our How to Invest in Dyadic International guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyadic International. If investors know Dyadic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyadic International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.27) | Revenue Per Share 0.062 | Quarterly Revenue Growth (0.54) | Return On Assets (0.46) | Return On Equity (1.27) |
The market value of Dyadic International is measured differently than its book value, which is the value of Dyadic that is recorded on the company's balance sheet. Investors also form their own opinion of Dyadic International's value that differs from its market value or its book value, called intrinsic value, which is Dyadic International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyadic International's market value can be influenced by many factors that don't directly affect Dyadic International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyadic International's value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyadic International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyadic International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.